MAPK8 and hepatocellular carcinoma: Using a JNK specific inhibitor, Hagiwara et al. [20] found that the xenografted CD133+ cells could be reduced in athymic mice, which identified that the therapeutic reaction of HCC patients to sorafenib was negatively correlated with CD133 expression and JNK pathway activity.